Live tape
Top 8, mentions 7d9,857TSLA2,037 mentions▲ +0.05GOOGL1,585 mentions▲ +0.04NVDA1,207 mentions▲ +0.07CRWV1,197 mentions▲ +0.03SPCX1,070 mentions▲ +0.07QQQ1,042 mentions▲ +0.04META874 mentions▲ +0.05NBIS845 mentions▲ +0.05

Equity · Healthcare

IDYA

NASDAQ

IDEAYA Biosciences, Inc.

$35.99 +0.28% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close)
Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for IDYA to draw a line in its place.

Track this symbol on TradingView TradingView chart
Market cap $3.5B
52-week range $21.42 – $41
Avg volume 281.4K

as of Jul 17, 2026

IDYA insider trades

SEC Form 4 · last 90 days · newest reported trade 6 Oct 2026
Open-market buys 0
Open-market sells 1
Net sold $985K
Non-trade filings 1
Date Insider Type Shares Value
06 Oct 2026 Hata Yujiro S President and CEO Sell 26,338 $985K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
06 Oct 2026 Hata Yujiro S President and CEO Option exercise 26,338 $114K

IDYA reported financials

SEC EDGAR XBRL SEC EDGAR

IDYA reported revenue of $218.7M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$113.7M.

Figure Reported Period
Revenue $218.7M 31 Dec 2025 fiscal year
Net income −$113.7M 31 Dec 2025 fiscal year
Diluted EPS −$1.28 31 Dec 2025 fiscal year
Total assets $1.3B 30 Jun 2026 at period end
Total equity $1.2B 30 Jun 2026 at period end

IDYA earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$1.22 $9M
31 Mar 2026 Q1 2026 −$1.11 $7M
31 Dec 2025 FY 2025 −$1.28 $219M
30 Sep 2025 Q3 2025 $1.33 $208M
30 Jun 2025 Q2 2025 −$0.88 —
31 Mar 2025 Q1 2025 −$0.82 —
31 Dec 2024 FY 2024 −$3.36 $7M
30 Sep 2024 Q3 2024 −$0.60 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

IDYA institutional holders

SEC Form 13F SEC EDGAR

10 of the 45 institutional funds we track reported a IDYA position for the quarter ended 30 Jun 2026 — a combined $256.8M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Added +26.9% shares 5,010,030 $186.7M
Fisher Asset Management Held (±25%) −3.6% shares 851,306 $31.7M
Citadel Advisors Trimmed −55.8% shares 300,438 $11.2M
Balyasny Asset Management Added +42.8% shares 297,565 $11.1M
Man Group Added +42.9% shares 245,492 $9.1M
AQR Capital Management Added +61.2% shares 67,976 $2.5M
Tudor Investment Corp Held (±25%) +6.0% shares 45,287 $1.7M
Two Sigma Investments Trimmed −65.4% shares 41,205 $1.5M
D. E. Shaw & Co. New position 20,763 $774K
Millennium Management Trimmed −95.4% shares 10,500 $391K

IDYA fails-to-deliver

SEC CNS data SEC

On 30 Sep 2026, 1,420 shares of IDYA failed to deliver (about $54K).

Settlement date Shares failed Notional % of shares out
30 Sep 2026 1,420 $54K 0.001%
28 Sep 2026 14,252 $523K 0.015%

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings